{"protocolSection": {"identificationModule": {"nctId": "NCT00530062", "orgStudyIdInfo": {"id": "IXR-404-04-167"}, "organization": {"fullName": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}, "briefTitle": "Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma", "officialTitle": "Comparison of Single-Dose Efficacy of Albuterol-HFA-BAI and Albuterol-HFA-MDI in Asthmatics With Poor Inhaler Coordinating Ability"}, "statusModule": {"statusVerifiedDate": "2022-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-07-25", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2008-10-24", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-10-24", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-09-14", "studyFirstSubmitQcDate": "2007-09-14", "studyFirstPostDateStruct": {"date": "2007-09-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2022-07-06", "resultsFirstSubmitQcDate": "2022-08-09", "resultsFirstPostDateStruct": {"date": "2022-08-31", "type": "ACTUAL"}, "dispFirstSubmitDate": "2017-10-12", "dispFirstSubmitQcDate": "2018-01-08", "dispFirstPostDateStruct": {"date": "2018-01-12", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-09-01", "lastUpdatePostDateStruct": {"date": "2022-09-07", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This is a research study designed to compare the single-dose efficacy of albuterol-hydrofluoroalkane-breath-actuated inhaler (HFA-BAI) and albuterol-HFA-metered-dose inhaler (MDI) in asthmatics with poor inhaler coordinating abilities."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma and Poor Coordinators of Asthma Inhalers"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 49, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Albuterol-HFA-BAI", "type": "EXPERIMENTAL", "description": "Participants will receive single actuation of albuterol 90 micrograms (mcg), administered using BAI in treatment period 1 or 2.", "interventionNames": ["Drug: Albuterol-HFA-BAI"]}, {"label": "Albuterol-HFA-MDI", "type": "ACTIVE_COMPARATOR", "description": "Participants will receive single actuation of albuterol 90 mcg, administered using MDI in treatment period 1 or 2.", "interventionNames": ["Drug: Albuterol-HFA-MDI"]}], "interventions": [{"type": "DRUG", "name": "Albuterol-HFA-MDI", "description": "Inhalation Aerosols, 90 mcg, 1 dose per treatment period", "armGroupLabels": ["Albuterol-HFA-MDI"], "otherNames": ["Albuterol", "ProAir"]}, {"type": "DRUG", "name": "Albuterol-HFA-BAI", "description": "Inhalation Aerosol (Breath-Actuated), 90 mcg, 1 dose per treatment period.", "armGroupLabels": ["Albuterol-HFA-BAI"], "otherNames": ["Albuterol"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Area-Under-the-Effect Curve of Percent Change in Test-Day Baseline Forced Expiratory Volume in 1 Second (FEV1) Versus Time (up to 2 Hours Postdose), %FEV1 AUEC0-2", "description": "The %FEV1 AUEC0-2 was calculated using the linear trapezoidal rule. The baseline value consisted of the average of the two predose FEV1 measurements. The mean was obtained from the mixed-effect analysis of variance adjusted for effects from the study center, the treatment sequence, and study period.", "timeFrame": "Baseline, Up to 2 hours postdose"}], "secondaryOutcomes": [{"measure": "Percent Change From Baseline in FEV1 Within 30 Minutes Postdose", "description": "The mean was obtained from the mixed-effect analysis of variance adjusted for effects from the study center, the treatment sequence, and study period.", "timeFrame": "Baseline up to 30 minutes postdose"}, {"measure": "Percent Change From Baseline in FEV1 up to 2 Hours Postdose", "description": "The mean was obtained from the mixed-effect analysis of variance adjusted for effects from the study center, the treatment sequence, and study period.", "timeFrame": "Baseline up to 2 hours postdose"}, {"measure": "Area-Under-the-Effect Curve of Change in Test-Day Baseline FEV1 Versus Time (up to 2 Hours Postdose), FEV1 AUEC0-2", "description": "The %FEV1 AUEC0-2 was calculated using the linear trapezoidal rule. The test-day baseline consisted of the average of the two predose FEV1 measurements. The mean was obtained from the mixed-effect analysis of variance adjusted for effects from the study center, the treatment sequence, and study period.", "timeFrame": "Baseline up to 2 hours postdose"}, {"measure": "Percentage of Participants With a 12% Increase From Baseline in FEV1 Within 2 Hours Postdose", "timeFrame": "Baseline up to 2 hours postdose"}, {"measure": "Percentage of Participants With a 15% Increase From Baseline in FEV1 Within 2 Hours Postdose", "timeFrame": "Baseline up to 2 hours postdose"}, {"measure": "Time to a 12% Increase From Baseline in FEV1 Within 2 Hours Postdose", "description": "The number of minutes required for the baseline FEV1 to increase by at least 12% within the 2-hour observation period. Median time and corresponding confidence intervals (CIs) were obtained via the Kaplan-Meier estimate.", "timeFrame": "Baseline up to 2 hours postdose"}, {"measure": "Time to a 15% Increase From Baseline in FEV1 Within 2 Hours Postdose", "description": "The number of minutes required for the baseline FEV1 to increase by at least 15% within the 2-hour observation period. Median time and corresponding CIs were obtained via the Kaplan-Meier estimate.", "timeFrame": "Baseline up to 2 hours postdose"}, {"measure": "Time to Maximum Increase in FEV1", "description": "Each calculation for FEV1 took several minutes in order to obtain the highest of 3 measurements. The total collection time exceeded the 120 mins post-dose time frame for some participants.", "timeFrame": "Baseline up to 2 hours postdose"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Asthma of a minimum of 6 months duration\n* Participants who demonstrate poor inhalation/actuation coordination when evaluated at screening utilizing the Aerosol Inhalation Monitor (AIM, Vitalograph) prior to any training and following training in 3 consecutive attempts\n* Reversible bronchoconstriction of \\>12% increase in FEV1 with a cumulative dose of 450 mcg of albuterol\n* The reversibility (FEV1) of \u226470% following administration of the initial 90 mcg of albuterol\n* Ability to perform spirometry reproducibly\n* Ability to self-perform peak expiratory flow (PEF) determinations and report scores on diaries\n* Can tolerate withdrawal of applicable medications for qualification at screening\n* Otherwise healthy individuals\n* Non-smokers for at least 2 years prior to the screening visit\n\nExclusion Criteria:\n\n* Allergy or sensitivity to albuterol\n* Exposure to investigational drugs within 30 days prior to the screening visit\n* Continuous treatment with beta-blockers, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, and/or systemic corticosteroids\n* Treated with oral or injectable corticosteroids within the 6 weeks prior to the screening visit\n* The prescribed dose regimen of any required antileukotrienes, inhaled corticosteroids and/or inhaled cromolyn and/or nedocromil had not been stable for at least 4 weeks prior to the screening visit\n* Inability to tolerate or unwillingness to comply with required washout periods for all applicable medications\n* Hospitalization for acute exacerbation of asthma more than twice in past year\n* Treatment in an emergency room or hospitalization for asthmatic symptoms within 3 months prior to the screening visit\n* An upper respiratory tract infection and/or sinusitis associated with exacerbation of asthma that is unresolved 3 weeks prior to the screening visit\n* History and/or presence of any clinically significant non-asthmatic acute or chronic disease\n* Known or suspected substance abuse\n* Previous enrollment in an IVAX Research-sponsored Albuterol-HFA asthma study Note: Other inclusion and exclusion criteria may apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "7 Years", "maximumAge": "70 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Teva Medical Expert, MD", "affiliation": "Teva Branded Pharmaceutical Products R&D, Inc.", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Clinical Study Site", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Teva Clinical Study Site", "city": "Lakewood", "state": "Colorado", "zip": "80401", "country": "United States", "geoPoint": {"lat": 39.70471, "lon": -105.08137}}, {"facility": "Clinical Study Site", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Clinical Study Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Clinical Study Site", "city": "Lake Oswego", "state": "Oregon", "zip": "97035", "country": "United States", "geoPoint": {"lat": 45.42067, "lon": -122.67065}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Eligible participants were randomized to receive the following 2 treatments on separate occasions 2-7 days apart: Albuterol-hydrofluoroalkane-breath-actuated inhaler (HFA-BAI) and Albuterol-HFA-metered-dose inhaler (MDI).", "groups": [{"id": "FG000", "title": "Overall Population", "description": "Participants received single actuation of albuterol 90 micrograms (mcg), administered using BAI in treatment period 1, then single actuation of albuterol 90 mcg, administered using MDI in treatment period 2. There was a washout period of 2-7 days between treatments."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "49"}]}, {"type": "Received at Least 1 Dose of Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "49"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "49"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Intent-to-treat (ITT) population included all randomized participants who took at least 1 dose of the assigned study medication.", "groups": [{"id": "BG000", "title": "Overall Population", "description": "Participants received single actuation of albuterol 90 mcg, administered using BAI in treatment period 1, then single actuation of albuterol 90 mcg, administered using MDI in treatment period 2. There was a washout period of 2-7 days between treatments."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "49"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "14.1", "spread": "9.59"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "27"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "22"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "11"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "38"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Race", "categories": [{"title": "Black or African heritage", "measurements": [{"groupId": "BG000", "value": "2"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "47"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Area-Under-the-Effect Curve of Percent Change in Test-Day Baseline Forced Expiratory Volume in 1 Second (FEV1) Versus Time (up to 2 Hours Postdose), %FEV1 AUEC0-2", "description": "The %FEV1 AUEC0-2 was calculated using the linear trapezoidal rule. The baseline value consisted of the average of the two predose FEV1 measurements. The mean was obtained from the mixed-effect analysis of variance adjusted for effects from the study center, the treatment sequence, and study period.", "populationDescription": "ITT population included all randomized participants who took at least 1 dose of the assigned study medication.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change from baseline*hour", "timeFrame": "Baseline, Up to 2 hours postdose", "groups": [{"id": "OG000", "title": "Albuterol-HFA-BAI", "description": "Participants received single actuation of albuterol 90 mcg, administered using BAI in treatment period 1"}, {"id": "OG001", "title": "Albuterol-HFA-MDI", "description": "Participants received single actuation of albuterol 90 mcg, administered using MDI in treatment period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "21.403", "spread": "2.263"}, {"groupId": "OG001", "value": "20.457", "spread": "2.253"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The analysis was performed using the mixed-effect analysis of variance with fixed effects of center, sequence, treatment group and period, and random effect of the participant within sequence.", "nonInferiorityType": "OTHER", "pValue": "0.5595", "pValueComment": "Threshold for significance at 0.05 level.", "statisticalMethod": "ANCOVA", "paramType": "Difference in adjusted mean", "paramValue": "0.946", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.293", "ciUpperLimit": "4.185"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in FEV1 Within 30 Minutes Postdose", "description": "The mean was obtained from the mixed-effect analysis of variance adjusted for effects from the study center, the treatment sequence, and study period.", "populationDescription": "ITT population included all randomized participants who took at least 1 dose of the assigned study medication.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Baseline up to 30 minutes postdose", "groups": [{"id": "OG000", "title": "Albuterol-HFA-BAI", "description": "Participants received single actuation of albuterol 90 mcg, administered using BAI in treatment period 1"}, {"id": "OG001", "title": "Albuterol-HFA-MDI", "description": "Participants received single actuation of albuterol 90 mcg, administered using MDI in treatment period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.777", "spread": "1.185"}, {"groupId": "OG001", "value": "10.114", "spread": "1.180"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in FEV1 up to 2 Hours Postdose", "description": "The mean was obtained from the mixed-effect analysis of variance adjusted for effects from the study center, the treatment sequence, and study period.", "populationDescription": "ITT population included all randomized participants who took at least 1 dose of the assigned study medication.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Baseline up to 2 hours postdose", "groups": [{"id": "OG000", "title": "Albuterol-HFA-BAI", "description": "Participants received single actuation of albuterol 90 mcg, administered using BAI in treatment period 1"}, {"id": "OG001", "title": "Albuterol-HFA-MDI", "description": "Participants received single actuation of albuterol 90 mcg, administered using MDI in treatment period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14.319", "spread": "1.292"}, {"groupId": "OG001", "value": "13.731", "spread": "1.286"}]}]}]}, {"type": "SECONDARY", "title": "Area-Under-the-Effect Curve of Change in Test-Day Baseline FEV1 Versus Time (up to 2 Hours Postdose), FEV1 AUEC0-2", "description": "The %FEV1 AUEC0-2 was calculated using the linear trapezoidal rule. The test-day baseline consisted of the average of the two predose FEV1 measurements. The mean was obtained from the mixed-effect analysis of variance adjusted for effects from the study center, the treatment sequence, and study period.", "populationDescription": "ITT population included all randomized participants who took at least 1 dose of the assigned study medication.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters*hours", "timeFrame": "Baseline up to 2 hours postdose", "groups": [{"id": "OG000", "title": "Albuterol-HFA-BAI", "description": "Participants received single actuation of albuterol 90 mcg, administered using BAI in treatment period 1"}, {"id": "OG001", "title": "Albuterol-HFA-MDI", "description": "Participants received single actuation of albuterol 90 mcg, administered using MDI in treatment period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.443", "spread": "0.044"}, {"groupId": "OG001", "value": "0.407", "spread": "0.044"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With a 12% Increase From Baseline in FEV1 Within 2 Hours Postdose", "populationDescription": "ITT population included all randomized participants who took at least 1 dose of the assigned study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline up to 2 hours postdose", "groups": [{"id": "OG000", "title": "Albuterol-HFA-BAI", "description": "Participants received single actuation of albuterol 90 mcg, administered using BAI in treatment period 1"}, {"id": "OG001", "title": "Albuterol-HFA-MDI", "description": "Participants received single actuation of albuterol 90 mcg, administered using MDI in treatment period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "57.1"}, {"groupId": "OG001", "value": "42.9"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With a 15% Increase From Baseline in FEV1 Within 2 Hours Postdose", "populationDescription": "ITT population included all randomized participants who took at least 1 dose of the assigned study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline up to 2 hours postdose", "groups": [{"id": "OG000", "title": "Albuterol-HFA-BAI", "description": "Participants received single actuation of albuterol 90 mcg, administered using BAI in treatment period 1"}, {"id": "OG001", "title": "Albuterol-HFA-MDI", "description": "Participants received single actuation of albuterol 90 mcg, administered using MDI in treatment period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "32.7"}, {"groupId": "OG001", "value": "30.6"}]}]}]}, {"type": "SECONDARY", "title": "Time to a 12% Increase From Baseline in FEV1 Within 2 Hours Postdose", "description": "The number of minutes required for the baseline FEV1 to increase by at least 12% within the 2-hour observation period. Median time and corresponding confidence intervals (CIs) were obtained via the Kaplan-Meier estimate.", "populationDescription": "ITT population included all randomized participants who took at least 1 dose of the assigned study medication.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "minutes", "timeFrame": "Baseline up to 2 hours postdose", "groups": [{"id": "OG000", "title": "Albuterol-HFA-BAI", "description": "Participants received single actuation of albuterol 90 mcg, administered using BAI in treatment period 1"}, {"id": "OG001", "title": "Albuterol-HFA-MDI", "description": "Participants received single actuation of albuterol 90 mcg, administered using MDI in treatment period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "60.00", "lowerLimit": "45.00", "upperLimit": "NA", "comment": "Due to smaller number of participants with an event, upper limit of 95% CI was not estimable."}, {"groupId": "OG001", "value": "NA", "lowerLimit": "46.00", "upperLimit": "NA", "comment": "Due to smaller number of participants with an event, median and upper limit of 95% CI was not estimable."}]}]}]}, {"type": "SECONDARY", "title": "Time to a 15% Increase From Baseline in FEV1 Within 2 Hours Postdose", "description": "The number of minutes required for the baseline FEV1 to increase by at least 15% within the 2-hour observation period. Median time and corresponding CIs were obtained via the Kaplan-Meier estimate.", "populationDescription": "ITT population included all randomized participants who took at least 1 dose of the assigned study medication.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "minutes", "timeFrame": "Baseline up to 2 hours postdose", "groups": [{"id": "OG000", "title": "Albuterol-HFA-BAI", "description": "Participants received single actuation of albuterol 90 mcg, administered using BAI in treatment period 1"}, {"id": "OG001", "title": "Albuterol-HFA-MDI", "description": "Participants received single actuation of albuterol 90 mcg, administered using MDI in treatment period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "123.0", "upperLimit": "NA", "comment": "Due to smaller number of participants with an event, median and upper limit of 95% CI was not estimable."}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Not enough participants experienced a 15% increase in FEV1 and therefore the median could not be calculated."}]}]}]}, {"type": "SECONDARY", "title": "Time to Maximum Increase in FEV1", "description": "Each calculation for FEV1 took several minutes in order to obtain the highest of 3 measurements. The total collection time exceeded the 120 mins post-dose time frame for some participants.", "populationDescription": "ITT population included all randomized participants who took at least 1 dose of the assigned study medication.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "minutes", "timeFrame": "Baseline up to 2 hours postdose", "groups": [{"id": "OG000", "title": "Albuterol-HFA-BAI", "description": "Participants received single actuation of albuterol 90 mcg, administered using BAI in treatment period 1"}, {"id": "OG001", "title": "Albuterol-HFA-MDI", "description": "Participants received single actuation of albuterol 90 mcg, administered using MDI in treatment period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "48.00", "lowerLimit": "15.00", "upperLimit": "123.0"}, {"groupId": "OG001", "value": "45.00", "lowerLimit": "11.00", "upperLimit": "128.0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From the day of study drug administration up to 30 days", "description": "Safety population included all randomized participants who took at least 1 dose of the assigned study medication.", "eventGroups": [{"id": "EG000", "title": "Albuterol-HFA-BAI", "description": "Participants received single actuation of albuterol 90 mcg, administered using BAI in treatment period 1", "deathsNumAffected": 0, "deathsNumAtRisk": 49, "seriousNumAffected": 0, "seriousNumAtRisk": 49, "otherNumAffected": 0, "otherNumAtRisk": 49}, {"id": "EG001", "title": "Albuterol-HFA-MDI", "description": "Participants received single actuation of albuterol 90 mcg, administered using MDI in treatment period 2.", "deathsNumAffected": 0, "deathsNumAtRisk": 49, "seriousNumAffected": 0, "seriousNumAtRisk": 49, "otherNumAffected": 0, "otherNumAtRisk": 49}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data."}, "pointOfContact": {"title": "Director, Clinical Research", "organization": "Teva Branded Pharmaceutical Products R&D, Inc.", "email": "USMedInfo@tevapharm.com", "phone": "1-888-483-8279"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000420", "term": "Albuterol"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "asFound": "Diameter", "relevance": "HIGH"}, {"id": "M19560", "name": "Procaterol", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}